Mechanisms of virus-induced asthma exacerbations: state-of-the-art. A GA²LEN and InterAirways document

Viral infections of the respiratory tract are the most common precipitants of acute asthma exacerbations. Exacerbations are only poorly responsive to current asthma therapies and new approaches to therapy are needed. Viruses, most frequently human rhinoviruses (RV), infect the airway epithelium, generate local and systemic immune responses, as well as neural responses, inducing inflammation and airway hyperresponsiveness. Using in vitro and in vivo experimental models the role of various proinflammatory or anti-inflammatory mediators, antiviral responses and molecular pathways that lead from infection to symptoms has been partly unravelled. In particular, mechanisms of susceptibility to viral infection have been identified and the bronchial epithelium appeared to be a key player. Nevertheless, additional understanding of the integration between the diverse elements of the antiviral response, especially in the context of allergic airway inflammation, as well as the interactions between viral infections and other stimuli that affect airway inflammation and responsiveness may lead to novel strategies in treating and/or preventing asthma exacerbations. This review presents the current knowledge and highlights areas in need of further research.

Epidemiological studies, with virological confirmation, have convincingly demonstrated that the majority of acute asthma exacerbations, in both children and adults, follow upper respiratory infections (1, 2). On some occasions, particularly young children, common colds are unique precipitants of wheezing and associated symptoms (3). However, much less is known about the mechanisms of virus-induced asthma exacerbations, than the relatively less frequent allergen-induced events.

An integrated response, aimed at the fast and efficient clearance of the invading pathogen, occurs during a respiratory viral infection. Elements of this response include the respiratory, the immune, as well as the nervous systems (4). The airway epithelium, site of viral
replication, generates an innate antiviral response, orchestrating downstream responses involving subepithelial and immune factors. An immune response is generated both locally and systemically, in order to preclude further viral invasion. Neural signals are generated in response to, or in an attempt to control or coordinate the inflammation. Several of these elements are altered in asthmatic individuals, resulting in induction of airway hyperresponsiveness (AHR) and contributing to the development of exacerbations consequent upon the infection (Fig. 1). Although not proven, mouth breathing or postnasal drip may also contribute to the clinical presentation of a respiratory viral infection (5). All respiratory viruses have been associated with asthma exacerbations; there is very little evidence on differential effects between these agents in their capacity to trigger asthma, nevertheless, the majority of relevant evidence comes from human rhinovirus (RV) studies.

Experimental models of virus-induced asthma

A variety of in vitro and in vivo models has been used for the study of virus-induced asthma. In vitro systems have most frequently been based upon continuous cell lines of bronchial epithelial origin, such as the BEAS-2B, A549, 16HBE and others (6). Cultures of human primary bronchial epithelial cells, obtained by bronchoscopy either by brushing or from biopsies, are preferable to continuous cell lines as they more closely represent in vivo conditions (7); more recently, differentiated primary epithelial cells, grown at an air-liquid interface, have been proposed to represent an optimal model for RV infection (8). Lung fibroblasts, either primary or continuous cell lines of embryonic origin (e.g. WI38) have also been popular, as fibroblasts support viral replication. Occasionally, smooth muscle cells, peripheral blood mononuclear cells (PBMC), monocytes, macrophages and eosinophils have been used either to assess viral replication or to model the antiviral immune response.

Small animal models of virus infections have been in use for a long time, with respect to influenza virus, respiratory syncytial virus, parainfluenza viruses (mostly Sendai virus in the mouse) as well as coronaviruses. Unfortunately, no practical small animal model of RV infection exists; thus for many years experimental RV infection in humans has been the model used to study RV infections. Over the past two decades several experimental studies have been carried out in both asthmatic and normal volunteers, with a good safety record. This approach offers a number of important advantages over studies of natural virus-induced asthma exacerbations, such as the ability to study subjects at baseline before infection; the selection of subjects according to specific criteria such as atopy, asthma severity and medication use; knowledge of the virus type and dose; accurate timing of investigations relative to the timing of infection; and the ability to carry out invasive investigations before, during and after infection, including bronchoscopy for sampling of the lower airway.

Experimental RV infection of asthmatics leads to an increase in lower respiratory tract symptoms typical of a mild asthma exacerbation (9, 10). These are accompanied by objective measures of increased airflow obstruction such as reduced peak expiratory flow (PEF) and forced expiratory volume (FEV1), and enhanced sensitivity to histamine (9, 11, 12). Few experimental infection studies have compared RV infection in asthmatic and normal subjects; however, to date it has not been demonstrated

Figure 1. Overview of virus-induced asthma exacerbations: respiratory viruses infect the airway epithelium inducing cellular damage, proinflammatory mediator production, a local and a systemic immune response and may affect neural homeostasis.
that experimental RV infection in asthmatics is associated with greater changes in lung function than in normals (9, 10), as is the case in naturally acquired infections in adults (13) and infants (14). The lack of a clear difference may be because of the inclusion of subjects with mild asthma only and the small number of subjects studied. Furthermore, the clinical, physiological and inflammatory responses to experimental RV infection in asthmatics are relatively mild compared with exacerbations induced by naturally acquired colds. This may be because of more complex interactions such as concomitant airway inflammation occurring in naturally acquired infections and leading to exacerbations.

**Virus-induced airway hyperresponsiveness**

Airway wall oedema, goblet cell metaplasia, altered surfactant function and mucus composition, due to cellular debris and plasma protein excess, modified patency of the small airways and increased epithelial and endothelial permeability, occur during viral infections and may lead to AHR (15, 16). Virus-induced epithelial damage causes narrowing through dead epithelial cells dropping into the lumen, decreased mucociliary clearance, increased exposure of sensory nerves to irritants, and decreased production of bronchodilating (PGE₂, NO, endopeptidase) and/or decreased metabolism of bronchoconstricting (substance P, neurokinin A) substances (17). Proinflammatory mediators, described below, may also contribute to AHR (18–21).

Viral infection induces greater nonspecific AHR in patients with respiratory allergy than healthy controls (22, 23). In addition, following a viral infection the response to allergen exposure may be exaggerated, as shown using bronchial provocations with allergen (24, 25). It has been suggested that the defective epithelial repair cycle, characteristic of asthma and strongly correlating with AHR, is amplified by exposure to Th2 cytokines (26). The duration of postviral AHR is around 7 weeks in children with intermittent asthma, comparable with studies prospectively evaluating postviral AHR in experimental animals (27, 28). Although the duration of AHR after a single cold is not affected by the atopic status of the patient, an increased number of symptomatic colds may cumulatively lead to prolonged AHR in atopic children (Fig. 2; 28). Taking into account that the degree of airway responsiveness is indicative of asthma severity and an indirect marker of airway inflammation (29), prolongation of virus-induced AHR may reflect persistent airway inflammation after multiple viral insults (30).

**Structural cells and extracellular matrix**

Respiratory viruses enter and replicate in epithelial cells lining the upper as well as the lower airways. Although RV in particular was considered in the past as an upper respiratory pathogen only, studies using polymerase chain reaction and in situ hybridization have conclusively shown that RV can also replicate in the lower airways (7, 14). The extent of epithelial cell destruction varies according to the type of virus. Influenza virus may cause extensive epithelial necrosis, whereas RV usually causes little or only patchy epithelial damage; in vitro, RV becomes cytotoxic under specific conditions (31). Death/damage of epithelial cells is likely to result in both an increase in epithelial permeability and an exposure of sensory nerve fibres to irritants and allergens. These effects may contribute to the increased AHR induced by respiratory viral infection. Dead epithelial cells, in addition to other inflammatory cells, dropping into the lumen may also contribute to airway obstruction (32).

Nevertheless, the lower airway epithelium does not simply act as a physical barrier but has an essential role in immune/inflammatory responses. Bronchial epithelial cells are major determinants of the inflammatory response through the production of a wide array of cytokines and chemokines, detailed below.

Adhesion molecules expressed on the surface of epithelial and endothelial cells are also involved in local inflammatory cell recruitment. One such molecule is ICAM-1 (CD54), the receptor for the majority of RVs and the natural ligand of the β₂-integrin CD11a. Viral infections upregulate the epithelial expression of ICAM-1 both in vivo and in vitro, supporting leucocyte infiltration, while potentially facilitating RV attachment and entry in host cells (33). A similar role could be attributed to vascular adhesion molecule-1 (VCAM-1; CD106), which

---

*Figure 2.* Duration of airway hyperresponsiveness (AHR) in atopic and nonatopic children with asthma, after an initial virus-induced exacerbation. An increased number of symptomatic infections leads to considerably prolonged AHR in the atopic group [adapted from Ref. (28)].
Epithelial cells may also act as antigen-presenting cells as they express major histocompatibility complex I and the costimulatory molecules CD80 (B7.1) and CD86 (B7.2), whose expression are upregulated in vitro by RV infection (35).

An important characteristic of the epithelium in asthma is the fact that it is particularly susceptible to injury (36). The imbalance between cell death and proliferation is considered crucial in the pathophysiology and pathology of the disease (37). Viruses may cause or interfere with such imbalance. For example, RV infection is able to delay epithelial repair (Fig. 3; 31). The degree of viral cytotoxicity not only depends upon the type of viral pathogen, but is also affected by the host epithelial cells. RV becomes highly cytotoxic only in sparsely cultured cells, a condition that may resemble the already disrupted epithelium occurring in asthma (31). When epithelial cells from patients with asthma were infected with RV in vitro, they were found to be resistant to early apoptosis, an effect caused by lack of the pro-apoptotic interferon (IFN)-β (38). Reduced apoptosis was associated with increased viral proliferation within the epithelial cells, resulting into increased cytotoxicity (38). Similar effects were observed when an epithelial cell line was conditioned by exposure to PBMC supernatants: immune cells deriving from atopic asthmatic individuals were unable to protect epithelial cells from RV-induced cytotoxicity (M. Xatzipsalti, unpublished data). Type I IFNs limit virus spread and prime neighbouring cells to an antiviral state. Recently, similar and even stronger effects were shown to occur through the newly described type III, or 7-interferons (39).

In addition to epithelial cells, RVs are capable of infecting airway smooth muscle (ASM) cells in vitro, inducing constrictor responsiveness and reducing β-adrenoceptor-mediated relaxation, although the clinical significance of this finding is uncertain (40). Submucosal gland (SMG) hypertrophy and mucus metaplasia with increased expression of the MUC5AC gene are seen in the asthmatic airways. Human SMG cells infected with RV produce IL-8, contributing to neutrophil inflammation and also augment eosinophil transmigration across the airway epithelium through the secretion of eosinophil chemotactic factors (RANTES, GM-CSF; 41). Increased numbers of mucus-producing goblet cells and increased staining for MUC5AC have also been observed in mice infected with Sendai virus (42) and RSV (43).

The major structural components of the airways, epithelium, underlying fibroblasts but also the matrix, interact dynamically. These structures (constituting the epithelial mesenchymal trophic unit) are physiologically active during lung morphogenesis in the fetus; it has been suggested that they are reactivated in asthma to drive pathological remodelling, in which the epithelium enters a chronic wound response, accompanied by production of profibrogenic growth factors (36). Virus-infected cells secrete increased amounts of fibroblast growth factor (FGF)-2 (44, 45) and vascular endothelial growth factor (VEGF; 46, 47). RV-induced VEGF was able to augment angiogenesis in an in vitro model (47). Furthermore, imbalance of matrix metalloproteinases regulating the deposition of collagen may also affect remodelling. Virus-induced proinflammatory cytokines stimulate the production and release of matrix metalloproteinase (MMP)-9 and MMP-2 by epithelial cells (48). This increase may allow extracellular matrix damage, possibly followed by abnormal mucosal repair in asthma.

**Immune cells and function**

**Neutrophils**

Neutrophils are among the predominant cell types participating in virus-induced asthma through generation of superoxide and/or release of cytokines. In nasopharyngeal aspirates and bronchial lavages, neutrophils are the main cells recruited during the acute stage of natural colds (49), probably via IL-8 or leukotriene B4 (50).

Adult patients, presenting to the emergency department with acute asthma and concomitant virus infection, had increased neutrophils and neutrophil elastase in sputum (51). Neutrophil proteases are potent secretagogues for airway SMGs (52) and can increase mucus production contributing to airway obstruction.

Neutrophils comprise the majority of nonepithelial cells in sputum during acute exacerbations of asthma (53). Experimental RV infection results in an increase in neutrophils in BAL (54) and sputum (55). In this model, peripheral blood neutrophil counts correlate with cold...
and asthma symptom scores (11), or signs in animals (56). Viruses can also activate neutrophil functions upregulating chemotaxis, adhesion and superoxide production (57).

Eosinophils

Viral infections can also trigger increased recruitment and activation of eosinophils, contributing to AHR (58–60). Rhinovirus experimental infections increase allergen-induced eosinophil numbers in bronchial lavage fluid in rhinitic adults (24) and eosinophil products in sputum supernatants in asthmatic adults (18). In vitro experiments indicate that RVs do not activate eosinophils directly (61), but probably through the activity of virus-induced mediators, adhesion molecules (33, 34) or cytokines secreted by T cells, epithelial cells or other airway cells (62).

A marked bronchial eosinophil infiltration has been observed during colds in both normal and asthmatic adults. However, the eosinophil infiltrate was more prolonged in asthmatic patients and still present 6–8 weeks after infection (59). Such differences have not, however, been confirmed in induced sputum (10).

Eosinophil granular proteins (e.g. major basic protein) have been detected in nasal secretions of asthmatic children with wheezing illness caused by RV or RSV (63, 64). In these children, RANTES and GM-CSF, factors affecting eosinophil recruitment, survival, degranulation and superoxide production, were also significantly increased (65).

Basophils and mast cells

In vitro incubation of basophils with viruses does not in itself cause release of mediators; however, some viruses (e.g. RSV, adenovirus and influenza) have been shown to enhance anti-immunoglobulin (Ig)E-mediated histamine release (66). These effects were shown to occur ex vivo with basophils from asthmatic volunteers during the acute phase compared with the convalescent phase of symptomatic colds, the increase in histamine and leukotriene release occurring in response to cross-linking of VLA 4 (67). Basophil activation could be mediated by interferons resulting from upper respiratory tract infection and enhancing histamine release (68). Nevertheless, systemic activation has not been confirmed in vivo during common colds (69).

The effect of viruses on mast cells have not been subject of much study, possibly because of the difficulty of obtaining adequate number of cells. Some animal studies on rat and calf are available (70, 71).

Dendritic cells

Pulmonary dendritic cells (DCs) express several ‘pathogen recognition receptors’, such as C-type lectins, mannose receptors and Toll-like receptors (TLRs), for efficient sensing and sampling of a wide variety of microbial organisms, including viruses. Whereas human plasmacytoid DCs express TLR7, which binds to single-stranded RNA (72) and TLR9, binding to CpG-rich DNA (73), CD11c+ human myeloid DCs express TLR3, a ligand for double-stranded (ds) RNA and TLR7 (74, 75). TLR 3, 7 and 9 specialize in viral detection and recognize nucleic acids in late endosomes-lysosomes, as these TLRs are localized to intracellular compartments (76).

Stimulation of human myeloid DCs and plasmacytoid DCs with synthetic TLR7 or TLR9 agonists induces the secretion of IL-12 and large amounts of IFN-α, respectively (75, 77). Toll-like receptor-mediated induction or modulation of type-1 interferons occurs in vitro after exposure of plasmacytoid DCs to RSV and influenza viruses, or epithelial cells to RV (78–80).

T and B lymphocytes

In the absence of infection, DCs isolated from the lungs express inducible costimulatory ligand (ICOSL) and secrete IL-10, selectively inducing regulatory T cells (81). After viral infections such as influenza, an optimal T-helper 1 (Th1) response is induced by lung DCs, leading to antigen-specific effector T cells producing IFN-γ and tumour necrosis factor (TNF). Virus-infected cells in the airway are thus recognized by Th1 CD4+ T cells and cytotoxic Tc1 CD8+ T cells. This recognition leads to killing of the infected cell and release of effector cell cytokines (such as IFN-γ), which further enhance the antiviral activities of the innate immune defence.

Indeed, bronchial biopsies have demonstrated increases in CD4+ and CD8+ T cells within the epithelium and submucosa of both healthy subjects and asthmatic patients following experimental RV infection (59). IFN-γ, together with type I interferons (IFN-α and IFN-β), play an important role in establishing a paracrine antiviral state. Whereas cytotoxic CD8+ T cells are a crucial player in protective cell-mediated immunity in response to respiratory viruses, a dysregulated CD8+ T-cell response in the context of a viral infection may place individuals with asthma at risk of severe asthma exacerbations, and even asthma death (82, 83).

The balance between Th1 and Th2 cytokine production can be crucial to viral clearance. It is well established that increased viral replication occurs under the influence of Th2 cytokines (84). Gern et al. found that the IFN-γ/IL-5 sputum mRNA ratio during infection was inversely related to peak cold symptom scores and time to virus clearance, suggesting that a strong Th1 response in the airway plays an important role in limiting the cold severity and viral replication (55). Exposure of PBMCs from normal and atopic asthmatic individuals to RV leads to the production of high levels of IFN-γ. Nevertheless, the levels are significantly lower in atopic asthmatic individuals; furthermore IL-4 production is

Virus-induced asthma exacerbations
upregulated only in these individuals, leading to considerable reduction of the IFN-γ/IL-4 ratio (85). In the same in vitro model, reduced expression of costimulatory molecules B7.1 and B7.2 and increased expression of the suppressor molecule CTLA-4 in CD4 T cells were observed in RV-exposed cells of atopic asthmatic individuals, suggesting that virus presentation may be suboptimal in these subjects (86).

The antiviral B cell immune response, as evidenced by immunoglobulin production, follows a tight time schedule (87). Mucosal IgA may be detected at day 3 after experimental virus infection, serum IgM at days 5–6 and IgG at days 7–8; all immunoglobulins increase in amount and avidity during the ensuing 2–3 weeks; their role seems to be less in direct virus eradication and more in the prevention of re-infection. However, it is not clear whether B-cell responses to respiratory virus infection are modified in the context of asthma.

Monocytes–macrophages
Alveolar macrophages make up the majority of cells seen in BAL from healthy individuals and asthmatic patients (88, 89). These residential macrophages are ideally placed for early phagocytosis and destruction of virus particles; moreover, human monocytes and macrophages express the major RV receptor ICAM-1. Entry of RV into monocytes leads to activation and production of TNF-α and IL-8 (90, 91). An earlier study reported that RV RNA synthesis was not detected in macrophages (90); however, recent study indicates that limited replication does take place in monocyte-derived macrophages (92), suggesting that macrophages may serve as permissive host cells during infection in vivo.

Mediators
Mediators produced by structural and immune cells upon a viral infection have regulatory and effector functions shaping the inflammatory response, both locally and systemically (Fig. 4). The epithelium alone is able to produce a broad range of mediators, including IL-1, IL-6, IL-8 (CXCL8), IL-11, TNF-α, GM-CSF, eotaxins (CCL10, 11, 24), RANTES (CCL5) and IP10 (CXCL10) (6, 93–101).

Interleukin-8 (IL-8) and granulocyte colony-stimulating factor (G-CSF) have been detected in nasal lavage and sputum after RV infection and correlate with nasal, sputum and blood neutrophils (55). One study has reported that IL-8 is increased in nasal lavage after RV infection in asthmatics but not in normals (102), although there is evidence of IL-8 upregulation during a natural RV infection in healthy students (M. Mäkelä, personal communication). In subjects with allergic rhinitis, RV infection increases production of the eosinophil chemokine eotaxin (103), together with eosinophil peroxidase and myeloperoxidase in nasal lavage (104). In normal subjects, experimental RV infection upregulates enzymes in the 5-lipoxygenase and cyclooxygenase pathways in the bronchial mucosa (105). Conversely RV infection increases exhaled nitric oxide (NO) levels in asthmatics and this is inversely correlated with the change in PC20, suggesting that NO may have a protective effect against virus-induced bronchial hyperreactivity (106). Overexpression of human β-defensin 2 in RV-infected epithelium suggests a potential mechanism linking the innate and specific immunity to the virus (107).

Although most of the above mediators are also found at elevated levels in allergic rhinitis and asthma (108), they are not unique to these diseases. Furthermore, many other processes (e.g. exposure to environmental smoke or diesel exhaust particles, wounding) that target or affect the integrity of the epithelium induce a similar response (109–112). Nevertheless, it is clear that through such mediators, viruses are able to potentiate inflammation as well as aggravate an underlying allergic response (11, 94, 113–116). Influx and activation of recruited or already present effector cells such as mast cells, eosinophils or neutrophils would lead to increased release of toxic components-like histamine, major basic protein, eosinophil cationic protein, eosinophil peroxidase and myeloperoxidase (117, 118). Tissue damage through these proteins may in itself contribute to the exacerbation. Furthermore, effector molecules, such as kinins (119) affect neural pathways inducing bronchoconstriction, as described below.

Viral infections are also able to induce systemic effects mediated by circulating cytokines, indicated by changes in leucocyte numbers following the infection. It is possible that through systemic effects upper airway infection may interfere with the bronchial allergic inflammation, as has been shown for allergen-induced inflammation through IL-5 (120). Nevertheless, the major inducible mediators after a respiratory viral infection are interferons (8). Interferon-mediated innate responses to viral infection are differentially regulated in normal or atopic asthmatic individuals and these differences may prove to be crucial in the development of acute exacerbations (38, 39, 85).

Neural mechanisms
Airway patency depends highly on smooth muscle constriction, mucosal oedema and mucus secretion, controlled by the adrenergic, cholinergic and the non-adrenergic noncholinergic (NANC) neural pathways.

Postviral alterations in neural control of the airways have been shown mainly in animal models, either through dysfunction of prejunctional M2-muscarinic inhibitory receptors, which normally inhibit acetylcholine release both directly and indirectly through production of IFN-γ.
(121), or through the release of bronchoconstricting neuropeptides (Fig. 5; 122–124).

Through the absence of the physical barrier, environmental irritants may directly stimulate unmyelinated sensory nerves. Released kinins may directly induce contraction of smooth muscle cells or lead to a parasympathetically induced bronchoconstriction. This effect may be aggravated by major basic protein that interferes with an M2 receptor-mediated autoinhibitory feedback loop that would normally keep this possible constriction in check. Enhanced neuronal activity will also lead to histamine release from mast cells that can be found in close proximity to nerve synapses. In addition, RSV infection induces changes in the mast cell-nerve synapses resulting in NK1 receptor upregulation and exacerbation of SP-induced bronchoconstriction and SM contraction (125, 126). Furthermore, it resulted in the release of cysLTs, which in turn amplified the release of tachykinins and potentiated their effects.

Increased NANC excitatory and decreased inhibitory responses have been noted after viral infections (56, 127). Parainfluenza and influenza viruses are cytotoxic to the epithelium, causing loss of neutral endopeptidase (NEP), the major tachykinin metabolizing enzyme, and hence loss of tachykinin-mediated control and consequent potentiation of their activities (121, 128). This is also the case for histamine methyltransferases. These enzymes would normally reduce tissue levels of histamine and kinins (129) and so dampen a given response.

In humans, normalization of the airway responses to challenges after atropine treatment suggests that sensory reflexes are abnormal after viral infections (130). Furthermore, effects of viral infection on the adrenergic
Molecular pathways

A considerable number of genes are upregulated upon viral infection of epithelial, immune or other cell types. Early events at the epithelial level, studied by use of a gene chip, include upregulation of many interferon-related genes (8). Subsequently, proinflammatory mediator genes are induced. Activation can be initiated by either receptor contact (e.g. ICAM-1) or virus replication, through the production of dsRNA and a dsRNA-dependent protein kinase pathway, as well as an IFN-β-mediated JAK-STAT pathway (8). None of these pathways is able to comprehensively explain all the observed effects at a cellular level, suggesting that multiple pathways are involved in a complex network. In this respect, poly-IC, a synthetic dsRNA analogue and TLR3 agonist, is not able to completely reproduce RV infection-mediated effects, although these are in part also mediated by TLR3 (78). From another perspective, dsRNA is also a potent stimulus of nitric oxide synthase 2 (NOS2) expression (133).

The ability of viral infections to activate transcription factors, notably NF-κB, seems to be a central event in the inflammatory response of the epithelium to infection. Adhesion molecules such as ICAM-1 and VCAM-1 (33, 34) or proinflammatory mediators including IL-1, IL-6, IL-8, IL-11 and GM-CSF have NF-κB sites in their promoter regions and have been shown to be upregulated through virus induction of this transcription factor (134). Nevertheless, NF-κB-independent pathways are also involved (135). Additional transcription factors such as AP-1 and GATA may be involved (33, 34). In human lymphocytes, NF-κB as well as NF-AT2 activation regulates IL-4 production, inducing a Th2 response after exposure to dsRNA. Transcriptional activation could be either direct, or mediated by other virus-induced events such as oxidative stress (136).

Upstream events required for cytokine transcription include phosphatidylinositol (PI)-3 kinase activation, required for IL-8 production, relating at least partly to viral endocytosis (137). Activation of p38 MAP kinase also seems to be a key event, as its blockage resulted in extensive inhibition of RV-induced production of multiple cytokines (138). Stimulation of p38 is mediated by the small G-protein RhoA through membrane rafts (139).

Genetic polymorphisms affecting the course or susceptibility to respiratory syncytial virus bronchiolitis are gaining attention (140, 141). As there are differences between acute bronchiolitis and asthma (142), further such studies in respect to asthma exacerbations are needed.

Interactions between viral infections and other factors

Viral infections, atopy and allergens

It is still uncertain if and to what extent asthmatic patients are more susceptible than normal individuals to airway infections. In a recent longitudinal study RV infections were similarly common in healthy and asthmatics; however, the degree of lower respiratory tract symptoms induced by the infection was more severe and prolonged in the asthmatic group (13). It had previously been suggested that the degree of antibody-mediated protection from RV infection is suboptimal in atopic subjects (143). Interestingly, the degree of worsening of asthma seems to be more pronounced in children with high IgE levels vs those with lower (144). Moreover, the odds ratio for wheezing is greater in children with RSV infection if they have evidence of atopy, supporting the theory of detrimental interaction between viruses and an allergic status in the infected patient (145). Nevertheless, it is now clear that the atopic/asthmatic condition may influence the outcome of viral infections independent of the presence of allergen (4, 85). On the other hand, epidemiological studies have shown that sensitized
allergic patients suffering from a viral infection have a very pronounced risk of developing a severe asthma worsening if they were concomitantly exposed to the relevant allergen, with an odds ratio of over 8 in adults (146) and almost 20 in children (147; Fig. 6). It is well established that when patients with mild rhinitis and/or asthma are experimentally infected with RV, a concomitant allergen challenge causes greater recruitment of eosinophils, more pronounced histamine release, enhanced bronchial hyperresponsiveness as well as increased risk of developing late asthmatic responses (25). Interestingly, when patients were exposed to RV after allergen exposure, no additive or synergistic effect on several inflammatory parameters was observed (148, 149). It seems therefore that timing of exposure may be important in a synergistic outcome, supported by recent in vitro (150) and animal findings (151).

Viral infections and air pollutants

Interactions between viral infection and air pollution have also been demonstrated. A recent study in Kenya monitoring exposure to indoor air pollution and health status of individuals showed a relationship between indoor pollution by biomass combustion and acute respiratory infections in adults and children (152). NO2 has received attention, as it can be emitted from both gas cooking appliances and motor vehicle exhausts, thus representing both an indoor and an outdoor pollutant. The Air Pollution on Health: European Approach (APHEA) project with data from 15 European cities has shown that an increase of 50 μg/m3 NO2 for 1 h was associated with a 2.6% increase in asthma admissions (153). Children exposed to increased levels of NO2 in school and home showed a significant increase in sore throat, colds and absences from school (154). When personal NO2 exposure and virus presence were assessed in a cohort of asthmatic children, high NO2 exposure was associated with higher infection rates and increased severity of virus-induced asthma symptoms (155). Furthermore, diesel particle exposure increases susceptibility to RSV infection (156) and upregulate RV receptors ICAM-1 and LDL (157).

Smokers have an increased risk for more frequent common colds with longer duration, as shown in epidemiological (158) and experimental infection studies (159). In children, environmental tobacco smoke (ETS) increases the risk of wheezing with colds (160), and asthma hospitalizations (161), possibly by an additive effect on atopic inflammation (162).

Conclusion and need for further research

Knowledge of the mechanisms of virus-induced asthma exacerbations has increased substantially in the last few years, although significant gaps still exist. Detailed studies of the molecular pathways that underlie virus-induced inflammation may help identify new therapeutic targets. While information on different aspects of the antiviral response is increasing, integration of the diverse elements and their interactions into a global model is still missing. In this respect, the role of neural elements in humans requires further attention. Further studies are also needed in order to differentiate between the response of normal and asthmatic individuals to viruses and to clarify the mechanisms that lead to increased severity and/or preclude resolution of infection in the latter. Furthermore, differentiation between atopic and nonatopic responses in asthma is still required, as the majority of studies have focused on atopic asthma. Finally, interactions between multiple triggers and their mechanisms, as well as the impact of virus-induced inflammation on subsequent tissue remodelling are only starting to be unravelled.

Figure 6. Synergistic effect of allergic sensitization, allergen exposure and viral infection in increasing the risk of hospitalization for asthma in children. Combined exposure and viral infection in sensitized children increased almost 20-fold such risk, while individual risk factor had weaker effects [adapted from Refs (146, 147)].

\[ \text{OR for asthma admission} \]

\begin{table}
\begin{tabular}{|c|c|c|c|c|c|c|}
\hline
 & Adults & & & & & \\
\hline
Sensitized & + & - & - & + & + & + \\
Exposed & - & + & - & + & + & + \\
Virus & - & + & + & + & + & + \\
\hline
\end{tabular}
\end{table}

\[ * P<0.05, ** P<0.01, *** P<0.001 \]
References

1. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs I et al. Community study of role of viral infections in exacerbations of asthma in 9–11 year old children. BMJ 1995;310:1225–1228.

2. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ 1993;307:982–986.

3. Silverman M, Wilson N. Wheezing phenotypes in childhood. Thorax 1997;52:936–937.

4. Papadopoulos NG, Velissariou I. The role of respiratory viruses in the pathogenesis of pediatric asthma. Pediatr Ann 2006;35:637–642.

5. Togias A. Systemic effects of local allergic disease. J Allergy Clin Immunol 2004;113:S8–14.

6. Subauste MC, Jacoby DB, Richards SM, Proud D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest 1995;96:549–557.

7. Papadopoulos NG, Bates PJ, Bardin PG, Papi A, Leir SH, Fraenkel DJ et al. Rhinoviruses infect the lower airways. J Infect Dis 2000;181:1875–1884.

8. Chen Y, Hamati E, Lee PK, Lee WM, Wachi S, Schnurr D et al. Rhinovirus induces airway epithelial gene expression through double-stranded RNA and IFN-dependent pathways. Am J Respir Cell Mol Biol 2006;34:192–203.

9. Bardin PG, Fraenkel DJ, Sanderson G, van Schalkwyk EM, Holgate ST, Johnston SL. Peak expiratory flow changes during experimental rhinovirus infection. Eur Respir J 2000;16:980–985.

10. Fleming HE, Little FF, Schnurr D, Avila PC, Wong H, Liu J et al. Rhinovirus-16 colds in healthy and in asthmatic subjects: similar changes in upper and lower airways. Am J Respir Crit Care Med 1999;160:100–108.

11. Grunberg K, Timmers M, Smits H, de Klerk E, Dick E, Spaan W et al. Effect of experimental rhinovirus 16 colds on airway hyperresponsiveness to histamine and interleukin-8 in nasal lavage in asthmatic subjects in vivo. Clin Exp Allergy 1997;27:36–45.

12. Grunberg K, Timmers MC, de Klerk EP, Dick EC, Sterk PJ. Experimental rhinovirus 16 infection causes variable airway obstruction in subjects with atopic asthma. Am J Respir Crit Care Med 1999;160:1375–1380.

13. Corne JM, Marshall C, Smith S, Schreiber J, Sanderson G, Holgate ST et al. Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet 2002;359:831–834.

14. Malmstrom K, Pitkaranta A, Carpen O, Pelkonen A, Malmberg LP, Turpeinen M et al. Human rhinovirus in bronchial epithelium of infants with recurrent respiratory symptoms. J Allergy Clin Immunol 2006;118:591–596.

15. Folkerts G, Busse WW, Nijkamp FP, Sorkness R, Gern JE. Virus-induced airway hyperresponsiveness and asthma. Am J Respir Crit Care Med 1998;157:1708–1720.

16. Dakhama A, Lee YM, Gelfand EW. Virus-induced airway dysfunction: pathogenesis and biomechanisms. Pediatr Infect Dis J 2005;24:159–169.

17. Hegele RG, Hayashi S, Hogg JC, Pare PD. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 1995;151:1659–1664.

18. Grunberg K, Smits H, Timmers M, de Klerk E, Dolhain R, Dick E et al. Experimental rhinovirus 16 infection. Effects on cell differentials and soluble markers in sputum in asthmatic subjects. Am J Respir Crit Care Med 1997;156:609–616.

19. Park JW, Taube C, Yang ES, Joetham A, Balhorn A, Takeda K et al. Respiratory syncytial virus-induced airway hyperresponsiveness is independent of IL-13 compared with that induced by allergen. J Allergy Clin Immunol 2003;112:1078–1087.

20. Schwarze J, Cieslewicz G, Joetham A, Ikemura T, Makela MJ, Dakhama A et al. Critical roles for interleukin-4 and interleukin-5 during respiratory syncytial virus infection in the development of airway hyperresponsiveness after airway sensitization. Am J Respir Crit Care Med 2000;162:380–386.

21. Schwarze J, Gelfand EW. Respiratory viral infections as promoters of allergic sensitization and asthma in animal models. Eur Respir J 2002;19:341–349.

22. Cheung D, Dick EC, Timmers MC, de Klerk EP, Spaan WJ, Sterk PJ. Rhinovirus inhibition causes long-lasting excessive airway narrowing in response to methacholine in asthmatic subjects in vivo. Am J Respir Crit Care Med 1995;152:1490–1496.

23. Gern JE, Calhoun W, Swenson C, Shen G, Busse WW. Rhinovirus infection preferentially increases lower airway responsiveness in allergic subjects. Am J Respir Crit Care Med 1997;155:1872–1876.

24. Calhoun W, Dick E, Schwartz L, Busse W. A common cold virus, rhinovirus 16, potentiates airway inflammation after segmental antigen bronchoprovocation in allergic subjects. J Clin Invest 1994;94:2290–2298.

25. Lemanske RF Jr, Dick EC, Swenson CA, Vrtis RF, Busse WW. Rhinovirus upper respiratory infection increases airway hyperreactivity and late asthmatic reactions. J Clin Invest 1989;83:1–10.

26. Davies DE, Wicks J, Powell RM, Puddicombe SM, Holgate ST. Airway remodeling in asthma: new insights. J Allergy Clin Immunol 2003;111:215–225; quiz 226.

27. Jafari HS, Chavez-Bueno S, Mejias A, Gomez AM, Rios AM, Nasi SS et al. Respiratory syncytial virus induces pneumonia, cytokine response, airway obstruction, and chronic inflammatory infiltrates associated with long-term airway hyperresponsiveness in mice. J Infect Dis 2004;189:1856–1865.

28. Xepapadaki P, Papadopoulos NG, Bossios A, Manousakis E, Manousakas T, Saxoni-Papageorgiou P. Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J Allergy Clin Immunol 2005;116:299–304.

29. O’Byrne PM, Inman MD. Airway hyperresponsiveness. Chest 2003;123:411S–416S.

30. Matsuse H, Behera AK, Kumar M, Rabb H, Lockey RF, Mohapatra SS. Recurrent respiratory syncytial virus infections in allergen-sensitized mice lead to persistent airway inflammation and hyperresponsiveness. J Immunol 2006;176:6583–6592.

31. Bossios A, Psarras S, Gourgiotis D, Skevaki CL, Constantopoulos AG, Saxoni-Papageorgiou P et al. Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. Respir Res 2005;6:114.

32. Holgate ST, Polosa R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet 2006;368:780–793.
33. Papi A, Johnston SL. Rhinovirus infection induces expression of its own receptor intercellular adhesion molecule 1 (ICAM-1) via increased NF-kappaB-mediated transcription. J Biol Chem 1999;274:9707–9720.
34. Papi A, Johnston SL. Respiratory epithelial cell expression of vascular cell adhesion molecule-1 and its up-regulation by rhinovirus infection via NF-kappaB and GATA transcription factors. J Biol Chem 1999;274:30041–30051.
35. Papi A, Stanciu LA, Papadopoulous NG, Teran LM, Holgate ST, Johnston SL. Rhinovirus infection induces major histocompatibility complex class I and costimulatory molecule upregulation on respiratory epithelial cells. J Infect Dis 2001;184:1780–1784.
36. Holgate ST, Holloway J, Wilson S, Bucchieri F, Puddicombe S, Davies DE. Epithelial-mesenchymal communication in the pathogenesis of chronic asthma. Proc Am Thorac Soc 2004;1:93–98.
37. Vignola AM, Gagliardi R, Siena A, Chiappara G, Bonsignore MR, Bousquet J et al. Airway remodeling in the pathogenesis of asthma. Curr Allergy Asthma Rep 2001;1:108–115.
38. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 2005;201:937–947.
39. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 2006;12:1023–1026.
40. Hakonarson H, Maskeri N, Carter C, Hodinka RL, Campbell D, Grunstein MM. Mechanism of rhinovirus-induced changes in airway smooth muscle responsiveness. J Clin Invest 1998;102:1732–1741.
41. Furukawa E, Ohrui T, Yamaya M, Suzuki T, Nakasato H, Sasaki T et al. Human airway submucosal glands augment eosinophil chemotaxis during rhinovirus infection. Clin Exp Allergy 2004;34:704–711.
42. Walter MJ, Morton JD, Kajiwara N, Agapov E, Holtzman MJ. Viral induction of a chronic asthma phenotype and genetic segregation from the acute response. J Clin Invest 2002;110:165–175.
43. Hashimoto K, Graham BS, Ho SB, Adler KB, Collins RD, Olsen SJ et al. Respiratory syncytial virus in allergic lung inflammation increases Muc5ac and gob-5. Am J Respir Crit Care Med 2004;170:306–312.
44. Hiu JJ, Liepkalns V, Azzarone B, Maceira-Coelho A. Metabolic changes in fibroblast adhesion sites induced by growth factors. Cell Biol Int Rep 1985;9:379–387.
45. Psarras S, Katsipatsi M, Volokon E, Bossios A, Gourgiotis D, Saxoni-Papageorgiou F et al. Rhinovirus infection stimulates production of fibroblast growth factor-2 by airway epithelial and stromal cells. Allergy 2002;57:528–536.
46. Lee CG, Yoon HJ, Zhu Z, Link H, Wang Z, Gwaltney JM et al. Respiratory syncytial virus stimulation of vascular endothelial cell growth factor/vascular permeability factor. Am J Respir Cell Mol Biol 2000;23:662–669.
47. Psarras S, Volokon E, Skevaki CL, Katsipatsi M, Bossios A, Pratsinis H et al. Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. J Allergy Clin Immunol 2006;117:291–297.
48. Yeo SJ, Yun YJ, Lyu MA, Woo SY, Woo ER, Kim SJ et al. Respiratory syncytial virus infection induces matrix metalloproteinase-9 expression in epithelial cells. Arch Virol 2002;147:229–242.
49. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD et al. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 1994;71:428–432.
50. Arnold R, Humbert B, Werchau H, Gallati H, Konig W, Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology 1994;82:126–133.
51. Wark PA, Johnston SL, Moric I, Simpson JLB, Hensley MJ, Gibson PG. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J 2002;19:68–75.
52. Schuster A, Fahy JV, Ueki I, Nadel JA. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors. Eur Respir J 1995;8:10–14.
53. Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 1995;95:843–852.
54. Jarjour NN, Gern JE, Kelly EA, Swenson CA, Dick CR, Busse WW. The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. J Allergy Clin Immunol 2000;105:1169–1177.
55. Gern JE, Vrtis R, Grindle KA, Swenson C, Busse WW. Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med 2000;162:2226–2231.
56. Folker G, Nijkamp FP. Virus-induced airway hyperresponsiveness. Role of inflammatory cells and mediators. Am J Respir Crit Care Med 1995;151:1666–1673.
57. Busse WW, Vrtis RF, Steiner R, Dick EC. In vitro incubation with influenza virus primes human polymorphonuclear leukocyte generation of superoxide. Am J Respir Cell Mol Biol 1991;4:347–354.
58. Wark PA, Gibson PG, Johnston SL. Exacerbations of asthma: addressing the triggers and treatments. Monaldi Arch Chest Dis 2001;56:429–435.
59. Fraenkel DJ, Bardin PG, Sanderson G, Lampe F, Johnston SL, Holgate ST. Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med 1995;151:879–886.
60. Grunberg K, Sharon RF, Sont JK, In ‘t Veen JC, Van Schadewijk WA, De Klerk EP et al. Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 2001;164:1816–1822.
61. Handzel ZT, Busse WW, Sedgwick JB, Vrtis R, Lee WM, Kelly EA et al. Eosinophils bind rhinovirus and activate virus-specific T cells. J Immunol 1998;160:1279–1284.
62. Gern J, Vrtis R, Kelly E, Dick E, Busse W. Rhinovirus produces nonspecific activation of lymphocytes through a monococyte-dependent mechanism. J Immunol 1996;157:1605–1612.
63. Garofalo R, Kimpen JL, Welliver RC, Ogura PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992;120:28–32.
64. Heymann P, Rakes G, Hogan A, Ingram J, Hoover G, Platt’s Mills T. Assessment of eosinophils, viruses and IgE antibody in wheezing infants and children. Int Arch Allergy Immunol 1995;107:380–382.
65. Teran LM, Seminario MC, Shute JK, Papi A, Compton SJ, Low JL et al. RANTES, macrophage-inhibitory protein 1 alpha, and the eosinophil product major basic protein are released into upper respiratory secretions during virus-induced asthma exacerbations in children. J Infect Dis 1999;179:677–681.
Papadopoulos et al.

66. Clementsén P, Kristensén KS, Norn S. Virus, bacteria and lipopolysaccharide increase basophil cell response to histamine releasing stimulators and calcium. Examination of allergic and normal individuals. Allergy 1991;46: 135–141.

67. Lavens SE, Goldring K, Thomas LH, Warner JA. Effects of integrin clustering on human lung mast cells and basophils. Am J Respir Cell Mol Biol 1996;14:95–103.

68. Ida S, Hooks JJ, Siragamani RP, Notkins AL. Enhancement of IgE-mediated histamine release from human basophils by viruses: role of interferon. J Exp Med 1977;145:892–906.

69. Makela MJ, Halminen M, Ruuskanen O, Puhakka T, Pirhonen J, Julkunen I et al. Lack of induction by rhinoviruses of systemic type I interferon production or enhanced MxA protein expression during the common cold. Eur J Clin Microbiol Infect Dis 1999;18:665–668.

70. Ogumbiyi PO, Black WD, Eyre P. Parainfluenza-3 virus-induced enhancement of histamine release from calf lung mast cells – effect of levamisole. J Vet Pharmacol Ther 1988;11:338–344.

71. Sorden SD, Castleman WL. Virus-induced increases in airway mast cells in brown Norway rats are associated with enhanced pulmonary viral replication and persisting lymphocytic infiltration. Exp Lung Res 1995;21:197–213.

72. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529–1531.

73. Krug A, Luker GD, Barchet W, Leib DA, Akira S, Colonna M. Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9. Blood 2004;103:1433–1437.

74. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004; 5:987–995.

75. Demedts IK, Brackle KR, Maes T, Joos GF, Brusselle GG. Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am J Respir Cell Mol Biol 2006;35:387–393.

76. Matsumoto M, Funami K, Tanabe M, Oshiumi H, Shingai M, Seto Y et al. Subcellular localization of Toll-like receptor 3 in human dendritic cells. J Immunol 2003; 171:3154–3162.
100. Terajama M, Yamaya M, Sekizawa K, Okinaga S, Suzuki T, Yamada N et al. Rhinovirus infection of primary cultures of human tracheal epithelium: role of ICAM-1 and IL-1beta. Am J Physiol 1997;273:L749–759.

101. Yamaya M, Sekizawa K, Suzuki T, Yamada N, Furukawa M, Ishizuka S et al. Infection of human respiratory submucosal glands with rhinovirus: effects on cytokine and ICAM-1 production. Am J Physiol 1999;277:L362–371.

102. de Kluijver J, Grunberg K, Pons D, de Klerk EP, Dick CR, Sterk PJ et al. Interleukin-1beta and interleukin-1ra levels in nasal lavages during experimental rhinovirus infection in asthmatic and non-asthmatic subjects. Clin Exp Allergy 2003;33:1415–1418.

103. Greiff L, Andersson M, Andersson E, Linden M, Myint S, Svensson C et al. Experimental common cold increases mucosal output of eotaxin in atopic individuals. Allergy 1999;54:1204–1208.

104. Greiff L, Venge P, Andersson M, Enander I, Linden M, Myint S et al. Effects of rhinovirus-induced common colds on granulocyte activity in allergic rhinitis. J Infect 2002;45:227–232.

105. Seymour ML, Gilby N, Bardin PG, Fraenkel DJ, Sanderson G, Penrose JF et al. Rhinovirus infection increases 5-lipoxygenase and cyclooxygenase-2 in bronchial biopsy specimens from non-atopic subjects. J Infect Dis 2002;185:540–544.

106. de Gouw HW, Grunberg K, Schot R, Kroeis AC, Dick EC, Sterk PJ. Relationship between exhaled nitric oxide and airway hyperresponsiveness following experimental rhinovirus infection in asthmatic subjects. Eur Respir J 1998;11:126–132.

107. Proud D. The role of defensins in virus-induced asthma. Curr Allergy Asthma Rep 2006;6:81–85.

108. Gelland EW. Inflammatory mediators in allergic rhinitis. J Allergy Clin Immunol 2004;114:S135–138.

109. Beisswenger C, Platz J, Seifart C, Vogelmeier C, Bals R. Exposure of differentiated airway epithelial cells to volatile smoke in vitro. Respiration 2004;71:402–409.

110. Gillitzer R, Goebeler M. Chemokines in cutaneous wound healing. J Leukoc Biol 2001;69:513–521.

111. Steerenberg PA, Zonneberg JA, Dormans JA, Joon PN, Wouters IM, van Bree L et al. Diesel exhaust particles induced release of interleukin 6 and 8 by (primed) human bronchial epithelial cells (BEAS 2B) in vitro. Exp Lung Res 1998;24:85–100.

112. Wang XP, Schunck M, Kallen KJ, Neumann C, Trautwein C, Rose-John S et al. The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol 2004;123:124–131.

113. Naclerio R, Proud D, Lichtenstein L, Kagey-Sobotka A, Hendley J, Sorrentino J et al. Kinins are generated during experimental rhinovirus colds. J Infect Dis 1988;157:133–142.

114. Proud D, Gwaltney JM, Hendley J, Dinarello C, Gillis S, Schleimer R. Increased levels of interleukin-1 are detected in nasal secretions of volunteers during experimental rhinovirus colds. J Infect Dis 1994;169:1007–1013.

115. Tanaka H, Miyazaki N, Oashi K, Teramoto S, Shiratori M, Hashimoto M et al. Nasal defense activity in mild and moderate asthma exacerbation. J Allergy Clin Immunol 2004;113:S135–138.

116. Turner RB, Weingand KW, Yeh CH, Leedy DW. Association between interleukin-8 concentration in nasal secretions and severity of symptoms of experimental rhinovirus colds [see comments]. Clin Infect Dis 1998;26:840–846.

117. Bienenstock J, Tomioka M, Matsuoka H, Stead RH, Quinonez G, Simon GT et al. The role of mast cells in inflammatory processes: evidence for nerve/mast cell interactions. Int Arch Allergy Appl Immunol 1987;82:238–243.

118. Goldie RG, Spina D, Henry PJ, Lulich KM, Paterson JW. In vitro responsive-ness of human alveolar bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline. Br J Clin Pharmacol 1986;22:669–676.

119. Jacoby DB. Virus-induced asthma attacks. JAMA 2002;287:755–761.

120. Braunstahl GJ, Overbeek SE, Kleinjan KM, Paterson JW. Nasal allergen provocation induces adhesin molecule expression and tissue eosinophilia in upper and lower airways. J Allergy Clin Immunol 2001;107:469–476.

121. Jacoby DB, Tamaoki J, Borson DB, Nadel JA. Virus induces airway hyperresponsive-ness to tachykinins: role of neutral endopeptidase. J Appl Physiol 1989;67:1504–1511.

122. Nakazawa H, Sekizawa K, Morikawa M, Yamauchi K, Sato M, Maeyama K et al. Viral respiratory infection causes airway hyperresponsiveness and decreases histamine N-methyltransferase activity in guinea pigs. Am J Respir Crit Care Med 1994;149:1180–1185.

123. Tripp RA, Barskey A, Goss L, Anderson LJ. Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection. J Neuroimmunol 2002;129:141–153.

124. Tripp RA, Jones L, Anderson LJ. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J Virol 2000;74:6227–6229.

125. King KA, Hu C, Rodriguez MM, Romagueria R, Jiang X, Piedimonte G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weaning rats. Am J Respir Cell Mol Biol 2001;24:101–107.

126. Piedimonte G, Rodriguez MM, King KA, Mohan SJ, Jiang X. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 1999;277:L831–840.

127. Colasurdo GN, Hemming VG, Prince GA, Loader JE, Graves JP, Larsen GL. Human respiratory syncytial virus affects nonadrenergic noncholinergic inhibition in cotton rat airways. Am J Physiol 1995;268:L1006–1011.

128. Dusser DJ, Jacoby DB, Djokic TD, Rubinstein I, Borson DB, Nadel JA. Virus induces airway hyperresponsive-ness to tachykinins: role of neutral endopeptidase. J Appl Physiol 1989;67:1504–1511.

129. Nakazawa H, Sekizawa K, Morikawa M, Yamauchi K, Sato M, Maeyama K et al. Viral respiratory infection causes airway hyperresponsiveness and decreases histamine N-methyltransferase activity in guinea pigs. Am J Respir Crit Care Med 1994;149:1180–1185.

130. Empey DW, Laitinen LA, Jacobs L, Gold WM, Nadel JA. Mechanisms of bronchial hyperreactivity in normal subjects after upper respiratory tract infection. Am Rev Respir Dis 1976;113:131–139.

131. Anderson GP. Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms. Clin Rev Allergy Immunol 2006;31:119–130.

132. Buckner CK, Clayton DE, Ain-Shoka AA, Busse WW, Dick EC, Shult P. Parainfluenza 3 infection blocks the ability of a beta adrenergic receptor agonist to inhibit antigen-induced contraction of guinea pig isolated airway smooth muscle. J Clin Invest 1981;67:376–384.
142. Heinzmann A, Arroliga ME, Erzurum SC, Double-stranded RNA dependence of nitric oxide synthase 2 expression in human bronchial epithelial cell lines BET-1A and BEAS-2B. Am J Respir Cell Mol Biol 2001; 24:720–726.

143. Bardin PG, Fraenkel DJ, Sanderson G, Dorward M, Lau LC, Johnston SL et al. Amplified rhinovirus colds in atopic subjects. Clin Exp Allergy 1994; 24:457–464.

144. Zambrano JC, Carper HT, Rakes GP, Patrie J, Murphy DD, Platts-Mills TAE et al. Experimental rhinovirus challenges in adults with mild asthma: response to infection in relation to IgE. J Allergy Clin Immunol 2003; 111:1008.

145. Rakes Gary P, Arruda E, Ingram Jim M, Hoover Gates E, Zambrano Juan C, Hayden Frederick G et al. Rhinovirus and respiratory syncytial virus in wheezing children requiring emergency care. IgE and eosinophil analyses. Am J Respir Crit Care Med 1999; 159:785–790.

146. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002; 324:763–766.

147. Murray CS, Poletti G, Kebadze T, Hunter J, Johnston SL et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax 2006; 61:376–382.

148. de Kluijver J, Evertse CE, Sont JK, Schrumpf JA, Zeijl-van der Ham CJG, Dick CR et al. Are rhinovirus-induced airway responses in asthma aggravated by chronic allergen exposure? Am J Respir Crit Care Med 2003; 168:1174–1180.

149. Avila PC, Abisheganaden JA, Wong H, Lui J, Yagi S, Schnurr D et al. Effects of allergic inflammation of the nasal mucosa on the severity of rhinovirus 16 colds. J Allergy Clin Immunol 2000; 105:923.

150. Bossios A, Psarras S, Gourgiotis D, Stavrinidis C, Saxoni-Papageorgiou P, Papadopoulos NG. Infection with human rhinovirus and exposure to Der p I synergize in ICAM-1 expression and IL-8 production by airway epithelial cells. XXIII Congress of European Academy of Allergology and Clinical Immunology, Amsterdam, 2004.

151. Barends M, Van Oosten M, De Rond CG, Dormans JA, Osterhaus AD, Neijens HJ et al. Timing of infection and prior immunization with respiratory syncytial virus (RSV) in RSV-enhanced allergic inflammation. J Infect Dis 2004; 189:1866–1872.

152. Ezzati M, Kammen DM. Indoor air pollution from biomass combustion and acute respiratory infections in Kenya: an exposure-response study. Lancet 2001; 358:619.

153. Tooulii M, Katsouyanni K, Zmirou D, Schwartz J, Spix C, de Leon AP et al. Short-term effects of ambient oxidant exposure on mortality: a combined analysis within the APHEA project. Air Pollution and Health: a European Approach. Am J Epidemiol 1997; 146:177–185.

154. Pilotto LS, Douglas RM, Attewell RG, Wilson SR. Respiratory effects associated with indoor nitrogen dioxide exposure in children. Int J Epidemiol 1997; 26:788–796.

155. Chauhan AJ, Inskipp HM, Linacher CK, Smith S, Schreiber J, Johnston SL et al. Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children. Lancet 2003; 361:1939.

156. Harrod KS, Jaramillo RJ, Rosenberger CL, Wang SZ, Berger JA, McDonald JD et al. Increased susceptibility to RSV infection by exposure to inhaled diesel engine emissions. Am J Respir Cell Mol Biol 2003; 28:451–463.

157. Ito T, Okumura H, Tsukue N, Kobayashi T, Honda K, Sekizawa K. Effect of diesel exhaust particles on expression of viral and bacterial receptors in rat lung epithelial L2 cells. Toxicol Lett 2006; 165:66–70.

158. Bensenor IM, Cook NR, Lee IM, Chown MJ, Hennekens CH, Buring JE et al. Active and passive smoking and risk of colds in women. Ann Epidemiol 2001; 11:225.

159. Cohen S, Tyrrell DA, Russell MA, Jarvis MJ, Smith AP. Smoking, alcohol consumption, and susceptibility to the common cold. Am J Public Health 1993; 83:1277–1283.

160. Cunningham J, O’Connor GT, Dockery DW, Speizer FE. Environmental tobacco smoke, wheezing, and asthma in children in 24 communities. Am J Respir Crit Care Med 1996; 153:218–224.

161. Venarske DL, Busse WW, Griffin MR, Gebretsadik T, Shintani AK, Minton PA et al. The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. J Infect Dis 2006; 193:1536–1543.

162. Franklin PJ, Turner S, Mutch R, Stick SM. Parental smoking increases exhaled nitric oxide in young children. Eur Respir J 2006; 28:730–733.